FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045846670> ?p ?o ?g. }

• W3045846670 abstract "The first biosimilar of recombinant follicle stimulating hormone (rFSH) launched in Europe was Bemfola® in 2014 following a clinical development programme demonstrating efficacy and safety to the satisfaction of the European Medicines Agency. Since then the increasing use of biosimilar rFSH has provided the opportunity to study both effectiveness across the whole population and the variation of rFSH use during routine clinical care in a real-world setting in Spain.This is a real-world study of 1222 women treated in 26 assisted reproduction treatment centres throughout Spain providing experience of the use of a biosimilar recombinant follicle stimulating hormone in four distinct populations. The four populations studied were poor responders, suboptimal responders, normal responders and oocyte donors. The primary endpoint was the total number of oocytes retrieved. Secondary endpoints included number of days of rFSH stimulation, total dose of rFSH administered, number of MII oocytes, number of fertilized oocytes, quality of embryos, number of embryos transferred, implantation rates, clinical pregnancy rates following embryo transfer, number of multiple pregnancies and number of serious adverse reactions, including moderate-to-severe OHSS.Differences were seen across the populations both in the characteristics of the women and ART outcomes suggestive of a continuum of fertility prognosis. In the poor responders, suboptimal responders, normal responders and oocyte donor populations the mean age in years was 39.9 (±SD 3.4), 38.4 (±SD 2.9), 34.4 (±SD 3.3) and 26 (±SD 4.6) respectively and number of oocytes retrieved was 4.1 (±SD 2.7), 8.6 (±SD 6.0), 12.2 (±SD 7.2) and 19.5 (±SD 9.5) respectively. The proportion of embryos graded as best quality was 18.5%, 33.0% and 43.8%, and graded as worst quality was 20.4%, 5.8% and 5.8% for poor responders, suboptimal responders and normal responders respectively. In a similar pattern, for poor responders, suboptimal responders and normal responders the implantation rates were 16.0%, (8/50), 22.4% (49/219), 30.6% (97/317) respectively and clinical pregnancy rates were 23.2% (10/43), 30.4% (59/194) and 37.0% (114/308) respectively. Adverse events were reported in only 7 of 1222 women (0.6%).Overall the results were consistent with the national ART results reported for Spain, hence this study provides reassurance of the clinical effectiveness of a biosimilar rFSH used in a real world setting.ClinicalTrials.gov identifier - NCT02941341." @default.
• W3045846670 created "2020-08-03" @default.
• W3045846670 creator A5043713321 @default.
• W3045846670 creator A5047854997 @default.
• W3045846670 creator A5049179497 @default.
• W3045846670 creator A5053375304 @default.
• W3045846670 creator A5057590788 @default.
• W3045846670 creator A5064946054 @default.
• W3045846670 creator A5077002007 @default.
• W3045846670 date "2020-07-29" @default.
• W3045846670 modified "2023-10-16" @default.
• W3045846670 title "The continuum of ovarian response leading to BIRTH, a real world study of ART in Spain" @default.
• W3045846670 cites W2011107313 @default.
• W3045846670 cites W2039104184 @default.
• W3045846670 cites W2048720395 @default.
• W3045846670 cites W2102259585 @default.
• W3045846670 cites W2115798190 @default.
• W3045846670 cites W2121430100 @default.
• W3045846670 cites W2124656409 @default.
• W3045846670 cites W2140474382 @default.
• W3045846670 cites W2169607300 @default.
• W3045846670 cites W2287315831 @default.
• W3045846670 cites W2583053728 @default.
• W3045846670 cites W2597415506 @default.
• W3045846670 cites W2605998378 @default.
• W3045846670 cites W2617113387 @default.
• W3045846670 cites W2619763997 @default.
• W3045846670 cites W2795364104 @default.
• W3045846670 cites W2883528578 @default.
• W3045846670 cites W3023643850 @default.
• W3045846670 cites W4254531755 @default.
• W3045846670 doi "https://doi.org/10.1186/s40738-020-00081-4" @default.
• W3045846670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7388222" @default.
• W3045846670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32742711" @default.
• W3045846670 hasPublicationYear "2020" @default.
• W3045846670 type Work @default.
• W3045846670 sameAs 3045846670 @default.
• W3045846670 citedByCount "5" @default.
• W3045846670 countsByYear W30458466702020 @default.
• W3045846670 countsByYear W30458466702022 @default.
• W3045846670 countsByYear W30458466702023 @default.
• W3045846670 crossrefType "journal-article" @default.
• W3045846670 hasAuthorship W3045846670A5043713321 @default.
• W3045846670 hasAuthorship W3045846670A5047854997 @default.
• W3045846670 hasAuthorship W3045846670A5049179497 @default.
• W3045846670 hasAuthorship W3045846670A5053375304 @default.
• W3045846670 hasAuthorship W3045846670A5057590788 @default.
• W3045846670 hasAuthorship W3045846670A5064946054 @default.
• W3045846670 hasAuthorship W3045846670A5077002007 @default.
• W3045846670 hasBestOaLocation W30458466701 @default.
• W3045846670 hasConcept C160099875 @default.
• W3045846670 hasConcept C16685009 @default.
• W3045846670 hasConcept C2776600139 @default.
• W3045846670 hasConcept C2777688143 @default.
• W3045846670 hasConcept C2778279030 @default.
• W3045846670 hasConcept C2779234561 @default.
• W3045846670 hasConcept C2781065240 @default.
• W3045846670 hasConcept C2908647359 @default.
• W3045846670 hasConcept C2910802627 @default.
• W3045846670 hasConcept C29456083 @default.
• W3045846670 hasConcept C500014431 @default.
• W3045846670 hasConcept C512716672 @default.
• W3045846670 hasConcept C518429986 @default.
• W3045846670 hasConcept C54355233 @default.
• W3045846670 hasConcept C71924100 @default.
• W3045846670 hasConcept C86803240 @default.
• W3045846670 hasConcept C99454951 @default.
• W3045846670 hasConceptScore W3045846670C160099875 @default.
• W3045846670 hasConceptScore W3045846670C16685009 @default.
• W3045846670 hasConceptScore W3045846670C2776600139 @default.
• W3045846670 hasConceptScore W3045846670C2777688143 @default.
• W3045846670 hasConceptScore W3045846670C2778279030 @default.
• W3045846670 hasConceptScore W3045846670C2779234561 @default.
• W3045846670 hasConceptScore W3045846670C2781065240 @default.
• W3045846670 hasConceptScore W3045846670C2908647359 @default.
• W3045846670 hasConceptScore W3045846670C2910802627 @default.
• W3045846670 hasConceptScore W3045846670C29456083 @default.
• W3045846670 hasConceptScore W3045846670C500014431 @default.
• W3045846670 hasConceptScore W3045846670C512716672 @default.
• W3045846670 hasConceptScore W3045846670C518429986 @default.
• W3045846670 hasConceptScore W3045846670C54355233 @default.
• W3045846670 hasConceptScore W3045846670C71924100 @default.
• W3045846670 hasConceptScore W3045846670C86803240 @default.
• W3045846670 hasConceptScore W3045846670C99454951 @default.
• W3045846670 hasIssue "1" @default.
• W3045846670 hasLocation W30458466701 @default.
• W3045846670 hasLocation W30458466702 @default.
• W3045846670 hasLocation W30458466703 @default.
• W3045846670 hasLocation W30458466704 @default.
• W3045846670 hasLocation W30458466705 @default.
• W3045846670 hasLocation W30458466706 @default.
• W3045846670 hasOpenAccess W3045846670 @default.
• W3045846670 hasPrimaryLocation W30458466701 @default.
• W3045846670 hasRelatedWork W1790516176 @default.
• W3045846670 hasRelatedWork W1969771329 @default.
• W3045846670 hasRelatedWork W1989301222 @default.
• W3045846670 hasRelatedWork W2007673126 @default.
• W3045846670 hasRelatedWork W2094795239 @default.
• W3045846670 hasRelatedWork W2583667225 @default.
• W3045846670 hasRelatedWork W2754999766 @default.

• next